Camzyos (Mavacamten) Patent Expiration, LOE Window & CMS Spending

Camzyos (Mavacamten) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2036-04-28, 0 AB generics, $319.2M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN214998 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-04-28
Last Listed Patent or Exclusivity Date2036-04-28
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$319.2M
2024 Medicare Part D Spend$290.8M
2024 Medicaid Spend$28.3M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.